EANS-Adhoc: LifeWatch Announces New "AF TeleClinic"

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

New Products/LifeWatch AG

11.05.2010

First in Series of Treatment-Specific Remote Patient Monitoring
Services

Chicago, IL / USA May 11 2010 - LifeWatch Services, Inc., a
subsidiary of LifeWatch AG (SIX Swiss Exchange: LIFE), will unveil
its advanced AF TeleClinic service offering this week at the Heart
Rhythm Society (HRS) Annual Meeting taking place in Denver, Colorado.
The AF TeleClinic service, empowered with the latest communication,
IT and medical technologies, ensures physicians are well equipped to
deliver optimal diagnostic and treatment options to their patients.
Featuring robust reporting options with key charting metrics, and a
comprehensive suite of workflow and data management tools for
monitoring Atrial Fibrillation patients, the AF TeleClinic aims to
improve the standards of care and clinical outcomes. The timely and
accurate reporting features of the AF TeleClinic can facilitate
better treatment options that improve a patient's quality of life,
and reduce unnecessary and costly hospital readmissions and emergency
room visits. Physicians further benefit from built-in processes
designed to streamline their practice workflows and provide staffing
efficiencies.

Atrial fibrillation, a disorder found in about 2.2 million Americans,
is a major cause of strokes in the U.S. Approximately 15 percent of
strokes occur in people with atrial fibrillation, and the likelihood
of developing this condition increases with age. Three to five
percent of people over 65 have atrial fibrillation. LifeWatch first
addressed this condition with its unique AF Patient Care monitoring
program in 2008.

"In evaluating the best solution for monitoring of our patients being
treated for Atrial Fibrillation, we selected the LifeWatch AF patient
care program which provides efficient patient scheduling and enhanced
arrhythmia reporting options", stated Vivek Reddy, MD, FHRS, FACC
Director, Cardiac Arrhythmia Service, The Leona M. and Harry B.
Helmsley Charitable Trust Professor of Medicine in Cardiac
Electrophysiology

Building on this highly successful program, LifeWatch designed the AF
TeleClinic with more advanced features and benefits that conform to
the new standards of practice and care for AF post procedure follow
up monitoring as recommended by the HRS consensus statement,
including:

* AF Ablation
* Drug Titration Therapy
* Cardioversion

The timesaving and cost-effective features of the AF TeleClinic
include automatic scheduling of patient follow up monitoring,
powerful reporting formats providing additional important data,
metrics and trending charts. For instance, an advanced "Afib" report
generates test-to-test serial comparative metrics for validation of
procedures, treatment success and efficacy. The seamless data
management and workflow algorithms increase staffing efficiencies and
free up time for non-administrative patient care duties that are more
critical.

The AF TeleClinic "first in the industry" bundled telemedicine
service, will be followed by a series of disease-specific monitoring
TeleClinics that LifeWatch is developing. Each LifeWatch TeleClinic
will provide a safe and effective care model outside of the costly in
hospital model. The integration of colliding technologies like remote
patient monitoring services, wireless communication platforms,
wearable technologies and Electronic Medical Records (EMR) serves to
proactively reduce LOS (Length of Stay) for patients in the hospital
and prevent unnecessary readmissions due to minor follow up
situations like compliance and false alarms. The use of advanced and
agnostic technologies will enable LifeWatch to collaborate with any
provider in the development of successful service models that ensure
the safety and well-being of patients in a timely manner.

"The launch of our first TeleClinic service offering is an exciting
opportunity which directly supports the emerging health care reform
initiatives in the U.S. " declared Brent Cohen, CEO, LifeWatch AG.
"As a pioneer in telemedicine, LifeWatch has a strong commitment to
develop advanced and cutting edge technologies that improve patient
outcomes, reduce the costs of care, and deliver valuable time
management processes that physicians need".

About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on
SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare
technology and solution company, specializing in advanced telehealth
systems and wireless remote patient monitoring services. LifeWatch
services cater to individuals, ranging from high-risk and chronically
ill patients, to consumers of health and wellness products. LifeWatch
has subsidiaries in the United States, the Netherlands, Japan, the
United Kingdom, Switzerland and Israel. LifeWatch AG is the parent
company of LifeWatch Services Inc., a leading US-based cardiac
monitoring service provider, and manufacturer of telecardiology
products. LifeWatch is also introducing a new program for Home
SleepTesting of Obstructive Sleep Apnea (OSA) patients under the
brand name NiteWatch. For additional information, please visit
www.lifewatch.com and www.nitewatchservices.com.

Sign-up for customized E-mail alerts and documentation requests is
available at http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding future results of
operations and financial position, business strategy and plans and
objectives for future operations, are forward-looking statements. The
words "believe," "may," "will," "estimate," "continue," "anticipate,"
"intend," "expect" and similar expressions are intended to identify
forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and
projections about future events and financial trends that it believes
may affect the financial condition, results of operations, business
strategy, short term and long term business operations and
objectives, and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions. In light
of these risks, uncertainties and assumptions, the forward-looking
events and circumstances described may not occur and actual results
could differ materially and adversely from those anticipated or
implied in the forward-looking statements. All forward-looking
statements are based only on data available to LifeWatch AG at the
time of the issue of this press release. LifeWatch AG does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH
AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN
INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH
AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE
OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S.
PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY
PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG
OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL
STATEMENTS OF THE ISSUER.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: LifeWatch AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Woo Kim, Senior Vice President of Strategy and Business Development, LifeWatch

Tel +1 847 813 4299 | Fax +1 847 813 24 48 | Email wkim@lifewatch.com

Sensus Investor and Public Relations GmbH, Zürich:

Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email lifewatch@sensus.ch

Branche: Healthcare Providers
ISIN: CH0012815459
WKN: 1281545
Index: SPI, SPIEX
Börsen: Frankfurt / Open Market / XETRA
SIX Swiss Exchange / Hauptsegment
Berlin / free trade